1 | resulting | 9,279 |
2 | culminating | 71 |
3 | hyper-connectivity | 3 |
4 | lexicalized | 3 |
5 | ω-diols | 3 |
6 | 'published | 2 |
7 | 0.10±0.01 | 2 |
8 | 33/30 | 2 |
9 | 399gln | 2 |
10 | absent/present/abundant | 2 |
11 | aphtha | 2 |
12 | apkcs | 2 |
13 | detaches | 2 |
14 | enamels | 2 |
15 | eventuating | 2 |
16 | garnishes | 2 |
17 | gse14407 | 2 |
18 | half-submerged | 2 |
19 | harris-shorr | 2 |
20 | macrodiscectomy | 2 |
21 | n'-disubstituted | 2 |
22 | o-bidentate | 2 |
23 | pneumonia/ardss | 2 |
24 | redisplacement/nonunion | 2 |
25 | rs3828610 | 2 |
26 | src-3/amplified | 2 |
27 | 'decline | 1 |
28 | 'probiotics | 1 |
29 | 'pumped | 1 |
30 | 'scenarios | 1 |
31 | +13/+17 | 1 |
32 | -5.9±6.5 | 1 |
33 | -8.1±6.4 | 1 |
34 | -patient | 1 |
35 | 0.04+/-3.94 | 1 |
36 | 0.23±0.04 | 1 |
37 | 0.28±0.01 | 1 |
38 | 0.4985 | 1 |
39 | 0.49±0.04 | 1 |
40 | 0.52±0.03 | 1 |
41 | 0.63/0.37 | 1 |
42 | 0.696+/-0.1 | 1 |
43 | 0.7406 | 1 |
44 | 0.745+/-0.03 | 1 |
45 | 0.82-fold | 1 |
46 | 0.83+/-3.88 | 1 |
47 | 0.86±0.51 | 1 |
48 | 0.87-0.87 | 1 |
49 | 09/gz/1081 | 1 |
50 | 1-15cm2 | 1 |
51 | 1.00-1.68 | 1 |
52 | 1.00/0.00 | 1 |
53 | 1.2-dicloroethane | 1 |
54 | 1.29-2.74 | 1 |
55 | 1.3db | 1 |
56 | 1.4-11.5 | 1 |
57 | 1.52-3.95 | 1 |
58 | 1.54-3.27 | 1 |
59 | 1.59+/-4.57 | 1 |
60 | 1.7±0.52 | 1 |
61 | 1.93±1.03 | 1 |
62 | 101.3±27.1 | 1 |
63 | 11,855 | 1 |
64 | 11cen-p14 | 1 |
65 | 12.57±2.05mg/dl | 1 |
66 | 12.7±7.9 | 1 |
67 | 12.7±9.5 | 1 |
68 | 134/qaly | 1 |
69 | 15.97±1.96mg/dl | 1 |
70 | 16±6°c | 1 |
71 | 18.0-30.4 | 1 |
72 | 182,546 | 1 |
73 | 2,777 | 1 |
74 | 2-dechloroethylifosfamide | 1 |
75 | 2-hydroxyisobutyrate | 1 |
76 | 2.18+/-0.76 | 1 |
77 | 2.4+/-0.3 | 1 |
78 | 2.9+/-1.3 | 1 |
79 | 20,290 | 1 |
80 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
81 | 268/1075 | 1 |
82 | 283/1072 | 1 |
83 | 3.1+/-1.6 | 1 |
84 | 31-60° | 1 |
85 | 32,110 | 1 |
86 | 4,4'-bipyridine-bridged | 1 |
87 | 4.1±1.2mm | 1 |
88 | 4.59±2.02 | 1 |
89 | 4.854 | 1 |
90 | 43.2mg | 1 |
91 | 4‒5 | 1 |
92 | 5.3±8.3weeks | 1 |
93 | 50.6-79.6 | 1 |
94 | 57°w | 1 |
95 | 61-90° | 1 |
96 | 64.4±27.5 | 1 |
97 | 7.1±13.9 | 1 |
98 | 7.98±0.41 | 1 |
99 | 77/111 | 1 |
100 | 7963 | 1 |
101 | 8-diones | 1 |
102 | 8-hydroxyclomipramine | 1 |
103 | 803a/a | 1 |
104 | 9.3/10 | 1 |
105 | 9890 | 1 |
106 | abstracts/papers | 1 |
107 | alkynyltrifluoroborate | 1 |
108 | amman-jordan | 1 |
109 | analysis.evidence | 1 |
110 | ancylostomideos | 1 |
111 | anemia/hemorrhage | 1 |
112 | angled-tip | 1 |
113 | antagonists-is | 1 |
114 | anti-c5 | 1 |
115 | anti-ca-present | 1 |
116 | anti-ro52 | 1 |
117 | antibiotics/steroids/antihistamines | 1 |
118 | aq-27 | 1 |
119 | arg41 | 1 |
120 | asp863 | 1 |
121 | azospermia | 1 |
122 | bafetinib | 1 |
123 | basophilia | 1 |
124 | belingai | 1 |
125 | biphenols | 1 |
126 | bsrt | 1 |
127 | c.279-280insat | 1 |
128 | c262y/wt | 1 |
129 | c282y/c282y | 1 |
130 | c7/th1 | 1 |
131 | ca/p-containing | 1 |
132 | cardiomagnyl | 1 |
133 | cassrs | 1 |
134 | cdxzn1-xse-cdyzn1-ys | 1 |
135 | cephalothorax | 1 |
136 | ci:0.95-2.43 | 1 |
137 | ci:0.99-2.51 | 1 |
138 | cns-lupus | 1 |
139 | co-organized | 1 |
140 | coiled-coils | 1 |
141 | core-ceramic/veneer | 1 |
142 | cowork | 1 |
143 | cpd-photolyase | 1 |
144 | cross-contaminations | 1 |
145 | crystallising | 1 |
146 | custom-manufactured | 1 |
147 | cutting-in | 1 |
148 | decentre | 1 |
149 | dederivation | 1 |
150 | desisting | 1 |
151 | digitalis-especially | 1 |
152 | dimission | 1 |
153 | disbalances | 1 |
154 | disulphides | 1 |
155 | dppc/pg | 1 |
156 | drb1*09012 | 1 |
157 | driving/riding | 1 |
158 | e-prints | 1 |
159 | edads | 1 |
160 | egerton | 1 |
161 | end-labeled | 1 |
162 | endo-1,4-β-mannanases | 1 |
163 | endo-1→3-β-d-glucanase | 1 |
164 | epilepsy/seizures | 1 |
165 | erinia | 1 |
166 | eskornade | 1 |
167 | esspecially | 1 |
168 | estrangement | 1 |
169 | f-e2 | 1 |
170 | f.c-e2 | 1 |
171 | feloten | 1 |
172 | ffar2 | 1 |
173 | folloed | 1 |
174 | framing-changing | 1 |
175 | g3pdhs | 1 |
176 | gender-sensitised | 1 |
177 | genno-shoko | 1 |
178 | h63d/h63d | 1 |
179 | heii-san | 1 |
180 | hexanedinitrile | 1 |
181 | hollow-structured | 1 |
182 | homovanillic-acid | 1 |
183 | hpa-3a | 1 |
184 | hsp84-transgene | 1 |
185 | hwangryun-hae-dok-decotion | 1 |
186 | hyper-proportional | 1 |
187 | ido1-overexpression | 1 |
188 | ii-article | 1 |
189 | illegally-engaged | 1 |
190 | imipramin | 1 |
191 | immune-isolated | 1 |
192 | ischémiques | 1 |
193 | ita-oba | 1 |
194 | jugal | 1 |
195 | kaitha | 1 |
196 | khorasan-1037 | 1 |
197 | laminin-2 | 1 |
198 | landmarked | 1 |
199 | lazanda® | 1 |
200 | ld3 | 1 |
201 | leukoerythroblastosis | 1 |
202 | lignosulfonates | 1 |
203 | lipocrits | 1 |
204 | lipomeningocele | 1 |
205 | liqpiritin | 1 |
206 | log-uacr | 1 |
207 | m3a | 1 |
208 | m3b | 1 |
209 | megusurino-ki | 1 |
210 | metallothione- | 1 |
211 | metxl50 | 1 |
212 | mg/al | 1 |
213 | miii | 1 |
214 | multicenter-trials | 1 |
215 | nival | 1 |
216 | notch1-4 | 1 |
217 | npnz | 1 |
218 | o-didesmethylvenlafaxine | 1 |
219 | obstruction/clogging | 1 |
220 | oprf/opri | 1 |
221 | orchid-epididymitis | 1 |
222 | p.l647f | 1 |
223 | painrelieving | 1 |
224 | particpation | 1 |
225 | pateint | 1 |
226 | pcrrflp | 1 |
227 | pdmpcisolated | 1 |
228 | peptidoleukotrienes | 1 |
229 | pg+cq | 1 |
230 | phloretin-3',5'-di-c-glucoside | 1 |
231 | pn1mi+ | 1 |
232 | pneuomothorax | 1 |
233 | polysaccharopeptide | 1 |
234 | polyuria/dehydration | 1 |
235 | preincubational | 1 |
236 | primases | 1 |
237 | progresssion | 1 |
238 | prostato-rectal | 1 |
239 | q-max | 1 |
240 | r=-0.032 | 1 |
241 | r=.87 | 1 |
242 | r=0.155 | 1 |
243 | rechu-to | 1 |
244 | regin | 1 |
245 | remobilisation | 1 |
246 | rfs/os | 1 |
247 | rionero | 1 |
248 | rs1054190c | 1 |
249 | rs12700667 | 1 |
250 | rs1413239 | 1 |
251 | rs1799836 | 1 |
252 | rs2099489 | 1 |
253 | rs628031 | 1 |
254 | rs8179090 | 1 |
255 | rs818571 | 1 |
256 | rs989692 | 1 |
257 | s3l1-s3l6 | 1 |
258 | s4l1-s4l5 | 1 |
259 | self-experiment | 1 |
260 | ser124 | 1 |
261 | serdang | 1 |
262 | sglp | 1 |
263 | sixty-day-old | 1 |
264 | srna162 | 1 |
265 | sulfaquinoxaline | 1 |
266 | synchronically | 1 |
267 | synthetically-challenging | 1 |
268 | tetra-capped | 1 |
269 | thr854 | 1 |
270 | total-isolates | 1 |
271 | triglyceride-content | 1 |
272 | trisome-18 | 1 |
273 | uaa-pi | 1 |
274 | univentricle | 1 |
275 | uraturia | 1 |
276 | uretro-rectal | 1 |
277 | varing | 1 |
278 | vegetating | 1 |
279 | yupingfeng-san | 1 |
280 | yupingfengsan | 1 |
281 | ~1.4-fold | 1 |
282 | ~2.1-fold | 1 |
283 | ~2.4-fold | 1 |
284 | ~5.0-fold | 1 |
285 | ~5.1-fold | 1 |
286 | ~5.4-fold | 1 |
287 | ~5.8-fold | 1 |
288 | ~8.3-fold | 1 |
289 | £12,834 | 1 |
290 | ¥74 | 1 |
291 | α=0.919 | 1 |
292 | β-1,3-galnac | 1 |
293 | €1,564 | 1 |
294 | €10,942/qaly | 1 |
295 | €12,122/qaly | 1 |
296 | €1590 | 1 |
297 | €209 | 1 |
298 | €2256 | 1 |
299 | €297 | 1 |
1 | 'decline | 1 |
2 | 'probiotics | 1 |
3 | 'published | 2 |
4 | 'pumped | 1 |
5 | 'scenarios | 1 |
6 | +13/+17 | 1 |
7 | -5.9±6.5 | 1 |
8 | -8.1±6.4 | 1 |
9 | -patient | 1 |
10 | 0.04+/-3.94 | 1 |
11 | 0.10±0.01 | 2 |
12 | 0.23±0.04 | 1 |
13 | 0.28±0.01 | 1 |
14 | 0.4985 | 1 |
15 | 0.49±0.04 | 1 |
16 | 0.52±0.03 | 1 |
17 | 0.63/0.37 | 1 |
18 | 0.696+/-0.1 | 1 |
19 | 0.7406 | 1 |
20 | 0.745+/-0.03 | 1 |
21 | 0.82-fold | 1 |
22 | 0.83+/-3.88 | 1 |
23 | 0.86±0.51 | 1 |
24 | 0.87-0.87 | 1 |
25 | 09/gz/1081 | 1 |
26 | 1-15cm2 | 1 |
27 | 1.00-1.68 | 1 |
28 | 1.00/0.00 | 1 |
29 | 1.2-dicloroethane | 1 |
30 | 1.29-2.74 | 1 |
31 | 1.3db | 1 |
32 | 1.4-11.5 | 1 |
33 | 1.52-3.95 | 1 |
34 | 1.54-3.27 | 1 |
35 | 1.59+/-4.57 | 1 |
36 | 1.7±0.52 | 1 |
37 | 1.93±1.03 | 1 |
38 | 101.3±27.1 | 1 |
39 | 11,855 | 1 |
40 | 11cen-p14 | 1 |
41 | 12.57±2.05mg/dl | 1 |
42 | 12.7±7.9 | 1 |
43 | 12.7±9.5 | 1 |
44 | 134/qaly | 1 |
45 | 15.97±1.96mg/dl | 1 |
46 | 16±6°c | 1 |
47 | 18.0-30.4 | 1 |
48 | 182,546 | 1 |
49 | 2,777 | 1 |
50 | 2-dechloroethylifosfamide | 1 |
51 | 2-hydroxyisobutyrate | 1 |
52 | 2.18+/-0.76 | 1 |
53 | 2.4+/-0.3 | 1 |
54 | 2.9+/-1.3 | 1 |
55 | 20,290 | 1 |
56 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
57 | 268/1075 | 1 |
58 | 283/1072 | 1 |
59 | 3.1+/-1.6 | 1 |
60 | 31-60° | 1 |
61 | 32,110 | 1 |
62 | 33/30 | 2 |
63 | 399gln | 2 |
64 | 4,4'-bipyridine-bridged | 1 |
65 | 4.1±1.2mm | 1 |
66 | 4.59±2.02 | 1 |
67 | 4.854 | 1 |
68 | 43.2mg | 1 |
69 | 4‒5 | 1 |
70 | 5.3±8.3weeks | 1 |
71 | 50.6-79.6 | 1 |
72 | 57°w | 1 |
73 | 61-90° | 1 |
74 | 64.4±27.5 | 1 |
75 | 7.1±13.9 | 1 |
76 | 7.98±0.41 | 1 |
77 | 77/111 | 1 |
78 | 7963 | 1 |
79 | 8-diones | 1 |
80 | 8-hydroxyclomipramine | 1 |
81 | 803a/a | 1 |
82 | 9.3/10 | 1 |
83 | 9890 | 1 |
84 | absent/present/abundant | 2 |
85 | abstracts/papers | 1 |
86 | alkynyltrifluoroborate | 1 |
87 | amman-jordan | 1 |
88 | analysis.evidence | 1 |
89 | ancylostomideos | 1 |
90 | anemia/hemorrhage | 1 |
91 | angled-tip | 1 |
92 | antagonists-is | 1 |
93 | anti-c5 | 1 |
94 | anti-ca-present | 1 |
95 | anti-ro52 | 1 |
96 | antibiotics/steroids/antihistamines | 1 |
97 | aphtha | 2 |
98 | apkcs | 2 |
99 | aq-27 | 1 |
100 | arg41 | 1 |
101 | asp863 | 1 |
102 | azospermia | 1 |
103 | bafetinib | 1 |
104 | basophilia | 1 |
105 | belingai | 1 |
106 | biphenols | 1 |
107 | bsrt | 1 |
108 | c.279-280insat | 1 |
109 | c262y/wt | 1 |
110 | c282y/c282y | 1 |
111 | c7/th1 | 1 |
112 | ca/p-containing | 1 |
113 | cardiomagnyl | 1 |
114 | cassrs | 1 |
115 | cdxzn1-xse-cdyzn1-ys | 1 |
116 | cephalothorax | 1 |
117 | ci:0.95-2.43 | 1 |
118 | ci:0.99-2.51 | 1 |
119 | cns-lupus | 1 |
120 | co-organized | 1 |
121 | coiled-coils | 1 |
122 | core-ceramic/veneer | 1 |
123 | cowork | 1 |
124 | cpd-photolyase | 1 |
125 | cross-contaminations | 1 |
126 | crystallising | 1 |
127 | culminating | 71 |
128 | custom-manufactured | 1 |
129 | cutting-in | 1 |
130 | decentre | 1 |
131 | dederivation | 1 |
132 | desisting | 1 |
133 | detaches | 2 |
134 | digitalis-especially | 1 |
135 | dimission | 1 |
136 | disbalances | 1 |
137 | disulphides | 1 |
138 | dppc/pg | 1 |
139 | drb1*09012 | 1 |
140 | driving/riding | 1 |
141 | e-prints | 1 |
142 | edads | 1 |
143 | egerton | 1 |
144 | enamels | 2 |
145 | end-labeled | 1 |
146 | endo-1,4-β-mannanases | 1 |
147 | endo-1→3-β-d-glucanase | 1 |
148 | epilepsy/seizures | 1 |
149 | erinia | 1 |
150 | eskornade | 1 |
151 | esspecially | 1 |
152 | estrangement | 1 |
153 | eventuating | 2 |
154 | f-e2 | 1 |
155 | f.c-e2 | 1 |
156 | feloten | 1 |
157 | ffar2 | 1 |
158 | folloed | 1 |
159 | framing-changing | 1 |
160 | g3pdhs | 1 |
161 | garnishes | 2 |
162 | gender-sensitised | 1 |
163 | genno-shoko | 1 |
164 | gse14407 | 2 |
165 | h63d/h63d | 1 |
166 | half-submerged | 2 |
167 | harris-shorr | 2 |
168 | heii-san | 1 |
169 | hexanedinitrile | 1 |
170 | hollow-structured | 1 |
171 | homovanillic-acid | 1 |
172 | hpa-3a | 1 |
173 | hsp84-transgene | 1 |
174 | hwangryun-hae-dok-decotion | 1 |
175 | hyper-connectivity | 3 |
176 | hyper-proportional | 1 |
177 | ido1-overexpression | 1 |
178 | ii-article | 1 |
179 | illegally-engaged | 1 |
180 | imipramin | 1 |
181 | immune-isolated | 1 |
182 | ischémiques | 1 |
183 | ita-oba | 1 |
184 | jugal | 1 |
185 | kaitha | 1 |
186 | khorasan-1037 | 1 |
187 | laminin-2 | 1 |
188 | landmarked | 1 |
189 | lazanda® | 1 |
190 | ld3 | 1 |
191 | leukoerythroblastosis | 1 |
192 | lexicalized | 3 |
193 | lignosulfonates | 1 |
194 | lipocrits | 1 |
195 | lipomeningocele | 1 |
196 | liqpiritin | 1 |
197 | log-uacr | 1 |
198 | m3a | 1 |
199 | m3b | 1 |
200 | macrodiscectomy | 2 |
201 | megusurino-ki | 1 |
202 | metallothione- | 1 |
203 | metxl50 | 1 |
204 | mg/al | 1 |
205 | miii | 1 |
206 | multicenter-trials | 1 |
207 | n'-disubstituted | 2 |
208 | nival | 1 |
209 | notch1-4 | 1 |
210 | npnz | 1 |
211 | o-bidentate | 2 |
212 | o-didesmethylvenlafaxine | 1 |
213 | obstruction/clogging | 1 |
214 | oprf/opri | 1 |
215 | orchid-epididymitis | 1 |
216 | p.l647f | 1 |
217 | painrelieving | 1 |
218 | particpation | 1 |
219 | pateint | 1 |
220 | pcrrflp | 1 |
221 | pdmpcisolated | 1 |
222 | peptidoleukotrienes | 1 |
223 | pg+cq | 1 |
224 | phloretin-3',5'-di-c-glucoside | 1 |
225 | pn1mi+ | 1 |
226 | pneumonia/ardss | 2 |
227 | pneuomothorax | 1 |
228 | polysaccharopeptide | 1 |
229 | polyuria/dehydration | 1 |
230 | preincubational | 1 |
231 | primases | 1 |
232 | progresssion | 1 |
233 | prostato-rectal | 1 |
234 | q-max | 1 |
235 | r=-0.032 | 1 |
236 | r=.87 | 1 |
237 | r=0.155 | 1 |
238 | rechu-to | 1 |
239 | redisplacement/nonunion | 2 |
240 | regin | 1 |
241 | remobilisation | 1 |
242 | resulting | 9,279 |
243 | rfs/os | 1 |
244 | rionero | 1 |
245 | rs1054190c | 1 |
246 | rs12700667 | 1 |
247 | rs1413239 | 1 |
248 | rs1799836 | 1 |
249 | rs2099489 | 1 |
250 | rs3828610 | 2 |
251 | rs628031 | 1 |
252 | rs8179090 | 1 |
253 | rs818571 | 1 |
254 | rs989692 | 1 |
255 | s3l1-s3l6 | 1 |
256 | s4l1-s4l5 | 1 |
257 | self-experiment | 1 |
258 | ser124 | 1 |
259 | serdang | 1 |
260 | sglp | 1 |
261 | sixty-day-old | 1 |
262 | src-3/amplified | 2 |
263 | srna162 | 1 |
264 | sulfaquinoxaline | 1 |
265 | synchronically | 1 |
266 | synthetically-challenging | 1 |
267 | tetra-capped | 1 |
268 | thr854 | 1 |
269 | total-isolates | 1 |
270 | triglyceride-content | 1 |
271 | trisome-18 | 1 |
272 | uaa-pi | 1 |
273 | univentricle | 1 |
274 | uraturia | 1 |
275 | uretro-rectal | 1 |
276 | varing | 1 |
277 | vegetating | 1 |
278 | yupingfeng-san | 1 |
279 | yupingfengsan | 1 |
280 | ~1.4-fold | 1 |
281 | ~2.1-fold | 1 |
282 | ~2.4-fold | 1 |
283 | ~5.0-fold | 1 |
284 | ~5.1-fold | 1 |
285 | ~5.4-fold | 1 |
286 | ~5.8-fold | 1 |
287 | ~8.3-fold | 1 |
288 | £12,834 | 1 |
289 | ¥74 | 1 |
290 | α=0.919 | 1 |
291 | β-1,3-galnac | 1 |
292 | ω-diols | 3 |
293 | €1,564 | 1 |
294 | €10,942/qaly | 1 |
295 | €12,122/qaly | 1 |
296 | €1590 | 1 |
297 | €209 | 1 |
298 | €2256 | 1 |
299 | €297 | 1 |
1 | pn1mi+ | 1 |
2 | metallothione- | 1 |
3 | 1.00/0.00 | 1 |
4 | 9.3/10 | 1 |
5 | 32,110 | 1 |
6 | rs3828610 | 2 |
7 | 33/30 | 2 |
8 | metxl50 | 1 |
9 | rs8179090 | 1 |
10 | 20,290 | 1 |
11 | €1590 | 1 |
12 | 9890 | 1 |
13 | 0.696+/-0.1 | 1 |
14 | 101.3±27.1 | 1 |
15 | 0.10±0.01 | 2 |
16 | 0.28±0.01 | 1 |
17 | 77/111 | 1 |
18 | rs628031 | 1 |
19 | 7.98±0.41 | 1 |
20 | arg41 | 1 |
21 | 0.86±0.51 | 1 |
22 | ci:0.99-2.51 | 1 |
23 | rs818571 | 1 |
24 | 09/gz/1081 | 1 |
25 | c7/th1 | 1 |
26 | laminin-2 | 1 |
27 | 4.59±2.02 | 1 |
28 | drb1*09012 | 1 |
29 | r=-0.032 | 1 |
30 | 1.7±0.52 | 1 |
31 | anti-ro52 | 1 |
32 | srna162 | 1 |
33 | 283/1072 | 1 |
34 | rs989692 | 1 |
35 | f.c-e2 | 1 |
36 | f-e2 | 1 |
37 | 1-15cm2 | 1 |
38 | ffar2 | 1 |
39 | 2.4+/-0.3 | 1 |
40 | 2.9+/-1.3 | 1 |
41 | 0.745+/-0.03 | 1 |
42 | 0.52±0.03 | 1 |
43 | 1.93±1.03 | 1 |
44 | ci:0.95-2.43 | 1 |
45 | asp863 | 1 |
46 | 7963 | 1 |
47 | ld3 | 1 |
48 | notch1-4 | 1 |
49 | 18.0-30.4 | 1 |
50 | -8.1±6.4 | 1 |
51 | 0.23±0.04 | 1 |
52 | 0.49±0.04 | 1 |
53 | 11cen-p14 | 1 |
54 | ser124 | 1 |
55 | £12,834 | 1 |
56 | 4.854 | 1 |
57 | thr854 | 1 |
58 | €1,564 | 1 |
59 | 1.29-2.74 | 1 |
60 | ¥74 | 1 |
61 | 0.04+/-3.94 | 1 |
62 | 1.4-11.5 | 1 |
63 | -5.9±6.5 | 1 |
64 | 64.4±27.5 | 1 |
65 | 12.7±9.5 | 1 |
66 | r=0.155 | 1 |
67 | 11,855 | 1 |
68 | 268/1075 | 1 |
69 | 0.4985 | 1 |
70 | 1.52-3.95 | 1 |
71 | anti-c5 | 1 |
72 | s4l1-s4l5 | 1 |
73 | 4‒5 | 1 |
74 | 3.1+/-1.6 | 1 |
75 | 50.6-79.6 | 1 |
76 | 0.7406 | 1 |
77 | rs1799836 | 1 |
78 | 182,546 | 1 |
79 | €2256 | 1 |
80 | 2.18+/-0.76 | 1 |
81 | s3l1-s3l6 | 1 |
82 | gse14407 | 2 |
83 | +13/+17 | 1 |
84 | aq-27 | 1 |
85 | 1.54-3.27 | 1 |
86 | 0.63/0.37 | 1 |
87 | khorasan-1037 | 1 |
88 | 1.59+/-4.57 | 1 |
89 | rs12700667 | 1 |
90 | 2,777 | 1 |
91 | 0.87-0.87 | 1 |
92 | r=.87 | 1 |
93 | €297 | 1 |
94 | trisome-18 | 1 |
95 | 1.00-1.68 | 1 |
96 | 0.83+/-3.88 | 1 |
97 | 7.1±13.9 | 1 |
98 | 12.7±7.9 | 1 |
99 | €209 | 1 |
100 | α=0.919 | 1 |
101 | rs1413239 | 1 |
102 | rs2099489 | 1 |
103 | 803a/a | 1 |
104 | hpa-3a | 1 |
105 | m3a | 1 |
106 | ita-oba | 1 |
107 | aphtha | 2 |
108 | kaitha | 1 |
109 | basophilia | 1 |
110 | azospermia | 1 |
111 | erinia | 1 |
112 | uraturia | 1 |
113 | m3b | 1 |
114 | 1.3db | 1 |
115 | bafetinib | 1 |
116 | rs1054190c | 1 |
117 | β-1,3-galnac | 1 |
118 | 16±6°c | 1 |
119 | h63d/h63d | 1 |
120 | illegally-engaged | 1 |
121 | 4,4'-bipyridine-bridged | 1 |
122 | half-submerged | 2 |
123 | 'published | 2 |
124 | src-3/amplified | 2 |
125 | landmarked | 1 |
126 | end-labeled | 1 |
127 | folloed | 1 |
128 | 'pumped | 1 |
129 | tetra-capped | 1 |
130 | custom-manufactured | 1 |
131 | hollow-structured | 1 |
132 | gender-sensitised | 1 |
133 | immune-isolated | 1 |
134 | pdmpcisolated | 1 |
135 | n'-disubstituted | 2 |
136 | lexicalized | 3 |
137 | co-organized | 1 |
138 | homovanillic-acid | 1 |
139 | sixty-day-old | 1 |
140 | ~5.0-fold | 1 |
141 | ~2.1-fold | 1 |
142 | ~5.1-fold | 1 |
143 | 0.82-fold | 1 |
144 | ~8.3-fold | 1 |
145 | ~1.4-fold | 1 |
146 | ~2.4-fold | 1 |
147 | ~5.4-fold | 1 |
148 | ~5.8-fold | 1 |
149 | analysis.evidence | 1 |
150 | eskornade | 1 |
151 | 2-dechloroethylifosfamide | 1 |
152 | phloretin-3',5'-di-c-glucoside | 1 |
153 | polysaccharopeptide | 1 |
154 | anemia/hemorrhage | 1 |
155 | univentricle | 1 |
156 | ii-article | 1 |
157 | lipomeningocele | 1 |
158 | hexanedinitrile | 1 |
159 | 1.2-dicloroethane | 1 |
160 | hsp84-transgene | 1 |
161 | sulfaquinoxaline | 1 |
162 | 'decline | 1 |
163 | 8-hydroxyclomipramine | 1 |
164 | o-didesmethylvenlafaxine | 1 |
165 | 20alpha-dihydroxypregn-4-en-3-one | 1 |
166 | decentre | 1 |
167 | endo-1→3-β-d-glucanase | 1 |
168 | cpd-photolyase | 1 |
169 | alkynyltrifluoroborate | 1 |
170 | 2-hydroxyisobutyrate | 1 |
171 | o-bidentate | 2 |
172 | p.l647f | 1 |
173 | 43.2mg | 1 |
174 | serdang | 1 |
175 | driving/riding | 1 |
176 | obstruction/clogging | 1 |
177 | framing-changing | 1 |
178 | synthetically-challenging | 1 |
179 | ca/p-containing | 1 |
180 | varing | 1 |
181 | crystallising | 1 |
182 | culminating | 71 |
183 | vegetating | 1 |
184 | eventuating | 2 |
185 | resulting | 9,279 |
186 | desisting | 1 |
187 | painrelieving | 1 |
188 | dppc/pg | 1 |
189 | belingai | 1 |
190 | miii | 1 |
191 | megusurino-ki | 1 |
192 | uaa-pi | 1 |
193 | oprf/opri | 1 |
194 | cowork | 1 |
195 | mg/al | 1 |
196 | jugal | 1 |
197 | preincubational | 1 |
198 | hyper-proportional | 1 |
199 | uretro-rectal | 1 |
200 | prostato-rectal | 1 |
201 | nival | 1 |
202 | 12.57±2.05mg/dl | 1 |
203 | 15.97±1.96mg/dl | 1 |
204 | cardiomagnyl | 1 |
205 | 4.1±1.2mm | 1 |
206 | amman-jordan | 1 |
207 | yupingfeng-san | 1 |
208 | heii-san | 1 |
209 | yupingfengsan | 1 |
210 | feloten | 1 |
211 | cutting-in | 1 |
212 | regin | 1 |
213 | imipramin | 1 |
214 | liqpiritin | 1 |
215 | 399gln | 2 |
216 | redisplacement/nonunion | 2 |
217 | ido1-overexpression | 1 |
218 | dimission | 1 |
219 | progresssion | 1 |
220 | particpation | 1 |
221 | polyuria/dehydration | 1 |
222 | remobilisation | 1 |
223 | dederivation | 1 |
224 | hwangryun-hae-dok-decotion | 1 |
225 | egerton | 1 |
226 | genno-shoko | 1 |
227 | rionero | 1 |
228 | rechu-to | 1 |
229 | angled-tip | 1 |
230 | pcrrflp | 1 |
231 | sglp | 1 |
232 | pg+cq | 1 |
233 | log-uacr | 1 |
234 | core-ceramic/veneer | 1 |
235 | harris-shorr | 2 |
236 | 'probiotics | 1 |
237 | apkcs | 2 |
238 | edads | 1 |
239 | disbalances | 1 |
240 | disulphides | 1 |
241 | detaches | 2 |
242 | garnishes | 2 |
243 | peptidoleukotrienes | 1 |
244 | antibiotics/steroids/antihistamines | 1 |
245 | 8-diones | 1 |
246 | epilepsy/seizures | 1 |
247 | primases | 1 |
248 | endo-1,4-β-mannanases | 1 |
249 | total-isolates | 1 |
250 | lignosulfonates | 1 |
251 | ischémiques | 1 |
252 | g3pdhs | 1 |
253 | antagonists-is | 1 |
254 | leukoerythroblastosis | 1 |
255 | orchid-epididymitis | 1 |
256 | 5.3±8.3weeks | 1 |
257 | multicenter-trials | 1 |
258 | enamels | 2 |
259 | coiled-coils | 1 |
260 | ω-diols | 3 |
261 | biphenols | 1 |
262 | cross-contaminations | 1 |
263 | rfs/os | 1 |
264 | ancylostomideos | 1 |
265 | 'scenarios | 1 |
266 | abstracts/papers | 1 |
267 | cassrs | 1 |
268 | pneumonia/ardss | 2 |
269 | lipocrits | 1 |
270 | e-prints | 1 |
271 | cns-lupus | 1 |
272 | cdxzn1-xse-cdyzn1-ys | 1 |
273 | c.279-280insat | 1 |
274 | absent/present/abundant | 2 |
275 | -patient | 1 |
276 | estrangement | 1 |
277 | self-experiment | 1 |
278 | anti-ca-present | 1 |
279 | triglyceride-content | 1 |
280 | pateint | 1 |
281 | bsrt | 1 |
282 | c262y/wt | 1 |
283 | 57°w | 1 |
284 | q-max | 1 |
285 | cephalothorax | 1 |
286 | pneuomothorax | 1 |
287 | c282y/c282y | 1 |
288 | €12,122/qaly | 1 |
289 | €10,942/qaly | 1 |
290 | 134/qaly | 1 |
291 | synchronically | 1 |
292 | digitalis-especially | 1 |
293 | esspecially | 1 |
294 | macrodiscectomy | 2 |
295 | hyper-connectivity | 3 |
296 | npnz | 1 |
297 | lazanda® | 1 |
298 | 31-60° | 1 |
299 | 61-90° | 1 |